1. Background {#sec2701}
=============

*Pseudomonas aeruginosa*, a versatile pathogen associated with a broad spectrum of infections in humans and widely known as an opportunistic organism, is frequently involved in infections among susceptible populations, especially patients with burns ([@A3546R1]). Furthermore, this organism possesses several virulence factors and is intrinsically resistant to most antimicrobials, a feature that is also responsible for the difficulty in treating infected patients ([@A3546R2]). In the past decade, *P. aeruginosa* strains showing resistance to multiple β-lactam antibiotics, in particular, metallo-β-lactamase (MBL)--producing *P. aeruginosa*, have become an increasing public health problem worldwide ([@A3546R3]-[@A3546R5]). Furthermore, infection with MBL-producing organisms is associated with higher rates of mortality, morbidity, and health care costs ([@A3546R6]-[@A3546R8]).

In *P. aeruginosa*, resistance to extended-spectrum β-lactams is mediated by lack of drug penetration, which may occur due to porin mutations, efflux pumps, or hydrolysis by β-lactamases ([@A3546R9]). On the basis of molecular studies, we can classify carbapenem-hydrolyzing enzymes into 4 groups: A, B, C, and D. The MBLs, which belong to group B, are enzymes that require divalent cations as cofactors for optimal enzyme activity and are inhibited by the action of a metal ion chelator. Hospital infections caused by *P. aeruginosa* are often difficult to eradicate because the organisms are resistant to drugs. Therefore, detection of MBL-producing *P. aeruginosa* is crucial to control the spread of resistance and for optimal treatment of patients, especially burn patients ([@A3546R10]). There is no information concerning the prevalence of MBL-producing *P. aeruginosa* strains in Kurdistan province.

2. Objectives {#sec2702}
=============

We conducted this study to detect MBL-producing strains among *P. aeruginosa* isolates obtained from burn patients at Tohid hospital, which is affiliated to Kurdistan University of Medical Sciences and has a burn unit with a heavy patient turnover and extensive antibiotic use.

3. Materials and Methods {#sec2703}
========================

Between April 2009 and April 2010, we isolated and identified 100 strains of *P. aeruginosa* in a clinical laboratory at Tohid hospital, Sanandaj, Iran. The strains were identified as *P. aeruginosa* on the basis of colony morphology, gram staining results, motility, oxidase reaction, production of the pyocyanin pigment, nitrate reduction, the use of citrate and malonate as carbon sources, and the ability to grow at 5˚C and 42˚C.

3-1. Antimicrobial Susceptibility Testing
-----------------------------------------

Antimicrobial susceptibility testing was done by the disk-diffusion method on Muller-Hinton agar (Merck, Germany) ([@A3546R11]). The following antibiotics were used: amikacin, gentamicin, carbencillin, ciprofloxacin, ofloxacin, cefepime, ceftazidime, cefotaxime, ampicillin, ceftriaxone, imipenem, and meropenem.

3-2. Detection of MBL
---------------------

Detection of MBL-producing *P. aeruginosa* strains was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines ([@A3546R11]). *P. aeruginosa* ATCC 27853 was used as the negative control. For the double-disk synergy test, the inoculum was prepared after emulsifying 5--6 colonies of the suspected isolate in Mueller--Hinton broth, and the turbidity was adjusted to 0.5 McFarland opacity standard. A lawn culture was obtained on Mueller--Hinton agar, and double-disk synergy test was performed.

3-3. Determination of Minimal Inhibitory Concentration
------------------------------------------------------

Imipenem minimal inhibitory concentration (MIC) was determined by microplate (NUNC, Denmark) broth dilution method on Mueller--Hinton agar. Zone diameter and MIC interpretive standards for breakpoints for *P. aeruginosa* published by CLSI were used ([@A3546R11]).

3-4 Genotypic Detection of VIM, SIM, and GIM MBL Genes by PCR
-------------------------------------------------------------

To detect VIM, SIM, and GIM MBL genes, PCR was performed for *P. aeruginosa* isolates ([@A3546R12])

4. Results {#sec2704}
==========

In this study, we identified 100 *P. aeruginosa* isolates among 176 clinical specimens obtained from patients. [Table 1](#tbl977){ref-type="table"} shows the antibiotic-resistance pattern of *P. aeruginosa* isolates. The isolates showed maximum resistance to ampicillin (100%), ceftazidime (94%), and ceftriaxone (89%). The next step in testing was designed to identify the MBL-producing *P. aeruginosa* strains. In the CLSI-MBL phenotypic test, of the 100 *P. aeruginosa* isolates, 22 (22%) were positive for MBL production by the double-disk synergy test ([Figure 1](#fig953){ref-type="fig"}).

###### In Vitro Antibiotic Resistance Pattern of Infection-Associated P. aeruginosa

  Antibiotic      Resistance, %
  --------------- ---------------
  Amikacin        52
  Gentamicin      54
  Carbencillin    76
  Ciprofloxacin   31
  Ofloxacin       82
  Cefepime        72
  Ceftazidime     96
  Cefotaxime      88
  Ampicillin      100
  ceftriaxone     89
  Imipenem        21
  Meropenem       14

![Phenotypic Detection of MBLs by DDST Among P. aeruginosa Isolates in Burn Patients at Tohid Hospital, Sanandaj, Iran](jjnpp-07-23-g001){#fig953}

4-1 Determination of MIC
------------------------

The MIC of MBL-positive isolates for imipenem is shown in [Table 2](#tbl978){ref-type="table"}; among 22 MBL-positive strains, 8 were resistant. PCR detection for MBL showed that 8 strains were positive for bla~VIM1~. The other genes, bla~SIM1~ and bla~GIM1~, were not detected ([Figure 2](#fig954){ref-type="fig"}).

###### MIC of MBL positive isolates for Imipenem

  Sensitive   Intermediate                         Resistant
  ----------- ------------------------------------ -----------
               MIC^a^, μg / ml                      
  ≤ 0.125     08                                   16
  0.25                                             32
  0.5                                              64
  01                                               128 ≤
  02                                                
  04                                                
              No. of *P. aeruginosa* Isolates, %    
  02          01                                   02
  02                                               01
  04                                               03
  02                                               02
  03                                                
  00                                                
              Total of *P. aeruginosa* Isolates     
  13          01                                   08

^a^Abbreviation: MIC: Minimum Inhitory Concentration
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5. Discussion {#sec2705}
=============

Because of its broad antimicrobial spectrum and stability against most common β-lactamases, imipenem generally represents one of the last alternatives for the treatment of nosocomial infections caused by multidrug-resistant gram-negative bacteria, particularly *P. aeruginosa* ([@A3546R13]). However, the rapid spread of MBLs among major gram-negative pathogens, particularly *P. aeruginosa*, is an emerging threat and a matter of concern worldwide ([@A3546R14]-[@A3546R16]); further, MBL-carrying bacteria are known to cause recalcitrant nosocomial infections ([@A3546R17]). MBLs of the IMP, VIM, and SIM families are frequently detected in imipenem-resistant *P. aeruginosa* in Iran ([@A3546R18]-[@A3546R20]). In our study, a total of 100 *P. aeruginosa* strains were isolated from hospitalized burn patients in Sanandaj, Iran, in 2010, and 22% of these strains were found to be MBL producers, which is much lower than the findings from the study conducted by Mihani and Khosravi in Ahvaz ([@A3546R18]). In this study, 22% of the imipenem-resistant *P. aeruginosa* isolates were MBL-positive, with 8% positive for VIM1, which is by far the most prevalent MBL in Iran^20^. To our knowledge, MBLs of other families like SIM have not been detected in *P. aeruginosa*. The prevalence of MBL-producing *P. aeruginosa* differs across Iranian studies, which may be because of differences in geographic regions. Further investigation is required to gain a better understanding of the epidemiology and genetic background of MBL-producing *P. aeruginosa*. The uncontrolled spread of MBL producers in hospitals may hamper treatment procedures and lead to increased morbidity and mortality. Systems for regular screening should be established to control the spread of MBL producers, and effective infection-control programs in hospitals should be developed and implemented thoroughly. The study results demonstrate the serious therapeutic threat of the spread of MBL-producing *P. aeruginosa*. This number (22% of imipenem-resistant *P. aeruginosa*) might have been higher if other genes were included. Early detection and infection control practices are the best defense against this organism; therefore, systematic surveillance to detect MBL producers is necessary.
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**Implication for health policy/practice/research/medical education:***Pseudomonas aeruginosa*, has showed up as a significant nosocomial pathogen particularly among burn patients. We have very scant information about the current state of Pseudomonas aeruginosa infections and their resistance pattern particularly ESBL. Moreover, with the increased use of prophylactic antibiotics to burn patients, careful surveillance of the changing trend of bacterial organisms and their antibiotic resistance pattern among neonates is warranted.
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